Quintiles and Quest Diagnostics Launch Q2 Solutions
Quintiles and Quest Diagnostics announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization.
Quintiles and Quest Diagnostics announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization. The launch of Q2 Solutions (pronounced Q Squared Solutions) is the result of the close of the previously announced http://www.appliedclinicaltrialsonline.com/quintiles-and-quest-diagnostics-form-joint-venture global clinical trials laboratory services joint-venture transaction. Quintiles owns 60% and Quest Diagnostics owns 40% of the two separate legal entities that comprise Q2 Solutions.
Q2 Solutions is now positioned as the second-largest global central laboratory services company. The two parent companies also have entered into a period of exclusive collaboration to explore how to use their data assets to enhance areas such as clinical trial patient recruitment and retention, clinical trial design as well as companion diagnostic development and commercialization.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
